A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
Study sponsor: COMPASS Pathways
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-09Estimated
Enrollment · participants102Actual
Source updated2025-08-19Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.